Description
RNK08954 is an investigational medication currently being studied in clinical trials for various types of solid tumors, including colorectal cancer (CRC). It is being evaluated in combination with another investigational drug called IN10018. The trials are in Phase 1, which means they are primarily focused on determining the safety of the drug combination and finding the right dose. Some trials specifically include patients with CRC whose tumors have certain mutations, like KRAS G12D or EGFR mutations. The goal is to see if this combination therapy is safe and shows early signs of effectiveness in these patients. As it is in early-phase trials, the long-term benefits and risks are still being evaluated.
Mechanism of Action
RNK08954 is being studied in combination with IN10018. The specific way RNK08954 works (its mechanism of action) is not fully detailed in the available information, but it is being investigated as part of a combination therapy for solid tumors with specific genetic mutations, such as KRAS G12D. The trials aim to determine the recommended dose for further studies and evaluate its potential anti-tumor effects and safety profile when used with IN10018.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.